TME parameters such as hypoxia and redox status, reflected by HIF-1α protein expression and glutathione (GSH) content in tumor tissue, can inform clinical decisions regarding VC monotherapy versus combination strategies. This evidence concerns the gene HIF1A and neoplasm.